Antibe Therapeutics Inc.
ATE
Hisse Senetlerindeki Sıralama
#31919
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Hisse Fiyatı
$0.21483059
Son senkronizasyon: 2024-05-07
Piyasa Değeri
$11.13M
Değişim (1 gün)
0.34%
Değişim (1 yıl)
-0.36%
Ülke
CA
Ticaret Antibe Therapeutics Inc. (ATE)
Kategori
Healthcare
Antibe Therapeutics Inc. (ATE) için EPS
2026 itibariyle EPS TTM: 0
Antibe Therapeutics Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
Antibe Therapeutics Inc. için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| Sağlanan tarihler için yeterli veri yok. | ||
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $3.11 | - |
US
|
|
| $3.59 | - |
IE
|
|
| $9.73 | - |
US
|
|
| $2.48 | - |
US
|
|
| - | - |
DE
|
